Oncology and Hematology News and Journal Articles

Diabetics at Increased Risk of Advanced Breast Cancer

Women with diabetes are at a greater risk of being diagnosed with advanced-stage breast cancer, according to a retrospective study. Image © 0833379753 /

Recent Content

Combination treatment with the PARP inhibitor olaparib plus the PI3K inhibitor BKM120 showed a benefit in subsets of breast cancer and ovarian cancer patients.

Men with metastatic castration-resistant prostate cancer that had mutations in DNA repair genes were more likely to respond to the PARP inhibitor olaparib.

Women who spend less time eating each day and an increased amount of hours fasting overnight had a decreased risk of breast cancer.

In an ongoing study, the immunotherapy MPDL3280A continues to be well-tolerated and to show signs of activity in triple-negative breast cancer patients.

Treatment with nivolumab and ipilimumab in patients with advanced melanoma produced significantly higher rates of response and progression-free survival compared with ipilimumab alone.

Treatment with pembrolizumab resulted in an estimated 6-month PFS rate that was almost double that of treatment with ipilimumab in advanced melanoma patients.

Ahead of the 2015 AACR Annual Meeting we discuss how insulin resistance relates to current cancer therapies.

By clicking Accept, you agree to become a member of the UBM Medica Community.